A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus



Status:Completed
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 55
Updated:10/11/2017
Start Date:March 31, 2008
End Date:December 18, 2008

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Double-blind, Randomized, Single Ascending Dose Escalation, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 Administered to Subjects With Type 1 Diabetes Mellitus

The purpose of this research study is to look at concentrations of GSK189075 in blood when
single doses of the drug are taken by mouth in combination with basal insulin. The clinical
effects of the drug in combination with insulin on the body will also be studied. The results
will help determine doses of GSK189075 can be studied in the future in the type I diabetes
mellitus population.


Inclusion Criteria:

- Adult male/female, 18 to 55 years old

- Diagnosis of type 1 diabetes mellitus for at least 6 months; and using a continuous
insulin pump

- Willing and able to follow all study-related instructions provided by the site staff.

- Willing to provide signed informed consent.

Exclusion Criteria:

- Pregnant or a nursing female.

- Have a past or current disease such as heart, liver, kidney, blood, brain, or other
disease.

- Have HIV or hepatitis, or have alcohol or drugs in your system at the screening visit.

- Have a history of alcohol abuse or have an eating disorder

- Have been in another research study in the last month or have taken certain
medications in the 1 week before study drug would be taken.
We found this trial at
1
site
GSK Investigational Site
San Diego, California 92111
?
mi
from
San Diego, CA
Click here to add this to my saved trials